EX-4.2



 Exhibit 4.2 
 THIS WARRANT HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “1933 ACT”), OR ANY APPLICABLE STATE SECURITIES LAWS, AND MAY NOT BE SOLD OR TRANSFERRED UNLESS
SUCH SALE OR TRANSFER IS IN ACCORDANCE WITH THE REGISTRATION REQUIREMENTS OF SUCH ACT AND APPLICABLE LAWS OR SOME OTHER EXEMPTION FROM THE REGISTRATION REQUIREMENTS OF SUCH ACT AND APPLICABLE LAWS IS AVAILABLE WITH RESPECT THERETO. 

PREFERRED STOCK PURCHASE WARRANT 
  

			
	Warrant
No.                                	  	Number of Shares: a maximum of 200,000
		  	 Series A Preferred Stock
 Subject to determination as set for the below


 FOUNDATION MEDICINE, INC. 

Effective as of November 1, 2010 
 Void after November 1, 2018, or earlier in accordance with 

Section 7 of this Warrant 
 1. Issuance. This Preferred Stock Purchase Warrant (the “Warrant”) is issued to LIGHTHOUSE CAPITAL PARTNERS VI, L.P. by
FOUNDATION MEDICINE, INC., a Delaware corporation (hereinafter with its successors called the “Company”) in connection with that certain Loan and Security Agreement No. 1881
dated November 1, 2010 between the Company and Lighthouse Capital Partners VI, L.P. (the “Loan Agreement”). Capitalized terms not defined herein shall have the meaning as set forth in the Loan Agreement. 

2. Purchase Price; Number of Shares. 
 (a) The registered holder of this Warrant (the “Holder”), is entitled upon surrender of this Warrant with the subscription form annexed hereto duly executed, at the principal
office of the Company, to purchase from the Company, at a price per share of $1.00 (the “Purchase Price”), up to a maximum of 200,000 fully paid and nonassessable shares of the Company’s Series A Preferred Stock, $0.0001 par
value (the “Preferred Stock”). Commencing on the date hereof, 100,000 (the “Exercise Quantity”) of shares of Preferred Stock are immediately available for purchase hereunder. 

(b) On the Commitment Termination Date or such earlier termination of this Warrant in accordance with the terms hereof, the
Exercise Quantity shall automatically be increased by such additional number of shares as is equal to (A) 2% of the amount of Aggregate Advances funded under the Loan Agreement, if any, divided by (B) the Purchase Price. 

In addition to other terms which may be defined herein, the following terms, as used in this Warrant, shall have the following meanings: 

 

	 	(i)	“Aggregate Advances” means the aggregate original dollar amount of Advances made under the Loan Agreement, whether such Advances are outstanding or
prepaid, at the time of any scheduled adjustment to the Exercise Quantity. 

 Until such time as this Warrant is exercised in full
or expires, the Purchase Price and the securities issuable upon exercise of this Warrant are subject to adjustment as hereinafter provided. The person or persons in whose name or names any certificate representing shares of Preferred Stock is issued
hereunder shall be deemed to have become the holder of record of the shares represented thereby as at the close of business on the date this Warrant is exercised with respect to such shares, whether or not the transfer books of the Company shall be
closed. 

  
 1. 









 3. Payment of Purchase Price. The Purchase Price may be paid (i) in cash or by
check, (ii) by the surrender by the Holder to the Company of any promissory notes or other obligations issued by the Company to the Holder, with all such notes and obligations so surrendered being credited against the Purchase Price in an
amount equal to the principal amount thereof plus accrued interest to the date of surrender, or (iii) by any combination of the foregoing. 
 4. Net Issue Election. The Holder may elect to receive, without the payment by the Holder of any additional consideration, shares of Preferred Stock equal to the value of this Warrant or any
portion hereof by the surrender of this Warrant or such portion to the Company, with the net issue election notice annexed hereto duly executed, at the principal office of the Company. Thereupon, the Company shall issue to the Holder such number of
fully paid and nonassessable shares of Preferred Stock as is computed using the following formula: 

X= Y(A-B) 
   A 
  

					
	        where:	  	X =	  	the number of shares of Preferred Stock to be issued to the Holder pursuant to this Section 4.
			
		  	Y =	  	the number of shares of Preferred Stock covered by this Warrant in respect of which the net issue election is made pursuant to this Section 4.
			
		  	A =	  	the Fair Market Value (defined below) of one share of Preferred Stock, as determined at the time the net issue election is made pursuant to this
Section 4.
			
		  	B =	  	the Purchase Price in effect under this Warrant at the time the net issue election is made pursuant to this Section 4.

 “Fair Market Value” of a share of Preferred Stock (or fully paid and nonassessable
shares of the Company’s common stock, $0.0001 par value (the “Common Stock”) if the Preferred Stock has been automatically converted into Common Stock) as of the date that the net issue election is made (the
“Determination Date”) shall mean: 
 (i) If the net issue election is made in connection with and
contingent upon the closing of the sale of the Company’s Common Stock to the public in a public offering pursuant to a Registration Statement under the 1933 Act (a “Public Offering”), and if the Company’s Registration
Statement relating to such Public Offering (“Registration Statement”) has been declared effective by the Securities and Exchange Commission, then the initial “Price to Public” specified in the final prospectus with respect
to such offering multiplied by the number of shares of Common Stock into which each share of Preferred Stock is then convertible. 
 (ii) If the net issue election is not made in connection with and contingent upon a Public Offering, then as follows: 
 (a) If traded on a securities exchange or NASDAQ market or system, the fair market value of the Common Stock shall be deemed to be the average of the closing or last reported sale prices of the
Common Stock on such exchange or market over the five day period ending five trading days prior to the Determination Date, and the fair market value of the Preferred Stock shall be deemed to be such fair market value of the Common Stock multiplied
by the number of shares of Common Stock into which each share of Preferred Stock is then convertible; 
 (b) If
otherwise traded in an over-the-counter market, the fair market value of the Common Stock shall be deemed to be the average of the closing ask prices of the Common Stock over the five day period ending five trading days prior to the Determination
Date, and the fair market value of the Preferred Stock shall be deemed to be such fair market value of the Common Stock multiplied by the number of shares of Common Stock into which each share of Preferred Stock is then convertible; and 

(c) If there is no public market for the Common Stock, then fair market value shall be determined in good faith by the
Company’s Board of Directors. 

  
 2. 









 5. Partial Exercise. This Warrant may be exercised in part at any time, and the
Holder shall be entitled to receive a new warrant, which shall be dated as of the date of this Warrant, covering the number of shares in respect of which this Warrant shall not have been exercised. 

6. Fractional Shares. In no event shall any fractional share of Preferred Stock be issued upon any exercise of this Warrant. If,
upon exercise of this Warrant in its entirety, the Holder would, except as provided in this Section 6, be entitled to receive a fractional share of Preferred Stock, then the Company shall pay the Holder an amount in cash equal to such
fraction of a share of Preferred Stock at such time. 
 7. Expiration Date; Automatic Exercise. This Warrant shall expire
at the earliest to occur of (the “Expiration Date”) (i) at the close of business on November 1, 2018; (ii) the second anniversary date of the effectiveness of the Company’s initial Public Offering; on the NASDAQ
or other stock exchange in the United States; or (iii) the effective date of a Merger (as defined below), and shall be void thereafter. 
 Notwithstanding the term of this Warrant fixed pursuant to this Section 7, and provided Holder has received advance written notice of at least twenty (20) days and has not earlier
exercised this Warrant, and provided this Warrant has not been assumed by the successor entity (or parent thereof), upon the consummation of a Merger (as defined below), this Warrant shall automatically be exercised pursuant to Section 4
hereof, without any action by Holder. “Merger” means: (i) a sale of all or substantially all of the Company’s assets to an Unaffiliated Entity (as defined below), or (ii) the merger, consolidation or acquisition of
the Company with, into or by an Unaffiliated Entity (other than a merger or consolidation for the principle purpose of changing the domicile of the Company or a bona fide round of preferred stock equity financing), that results in the transfer of
fifty percent (50%) or more of the outstanding voting power of the Company. “Unaffiliated Entity” means any entity that is owned or controlled by parties who own less than twenty percent (20%) of the combined voting power
of the voting securities of the Company immediately prior to such merger, consolidation or acquisition. Notwithstanding the foregoing, in the event that any outstanding warrants to purchase equity securities of the Company are assumed by the
successor entity of a Merger (or parent thereof), this Warrant shall also be similarly assumed. The Company agrees to promptly give the Holder written notice of any proposed Merger and written notice of termination of any proposed Merger.
Notwithstanding anything to the contrary in this Warrant, the Holder may rescind any exercise of its purchase rights after a notice of termination of the proposed Merger if the exercise of this Warrant occurred after the Company notified the Holder
that the Merger was proposed or if the exercise was otherwise precipitated by such proposed Merger, provided, however that such rescission right must be exercised within thirty (30) days of receipt of such written notice of termination of the
proposed Merger. In the event of such rescission, this Warrant will continue to be exercisable on the same terms and conditions. 
 8. Reserved Shares; Valid Issuance. The Company covenants that it will at all times from and after the date hereof reserve and keep available such number of its authorized shares of Preferred Stock
and Common Stock free from all preemptive or similar rights therein, as will be sufficient to permit, respectively, the exercise of this Warrant in full and the conversion into shares of Common Stock of all shares of Preferred Stock receivable upon
such exercise. The Company further covenants that such shares as may be issued pursuant to such exercise and/or conversion will, upon issuance, be duly and validly issued, fully paid and nonassessable and free from all taxes, liens and charges with
respect to the issuance thereof. 
 9. Stock Splits and Dividends. If after the date hereof the Company shall subdivide
the Preferred Stock, by split-up or otherwise, or combine the Preferred Stock, or issue additional shares of Preferred Stock in payment of a stock dividend on the Preferred Stock, the number of shares of Preferred Stock issuable on the exercise of
this Warrant shall forthwith be proportionately increased in the case of a subdivision or stock dividend, or proportionately decreased in the case of a combination, and the Purchase Price shall forthwith be proportionately decreased in the case of a
subdivision or stock dividend, or proportionately increased in the case of a combination. 
 10. Adjustments for Diluting
Issuances. The other antidilution rights applicable to the Preferred Stock of the Company are set forth in the Amended and Restated Certificate of Incorporation, as amended from time to time (the “Articles”), a true and complete
copy in its current form which is attached hereto as Exhibit A. Until full exercise or expiration of this Warrant, such rights shall not be restated, amended or modified in any manner which affects the Holder differently than the
holders of Preferred Stock without such Holder’s prior written consent, provided, however, that nothing herein shall be deemed to restrict the restatement, amendment or modification of the Articles, in accordance with the provisions of the
Articles, in a manner that affects equally all holders of Preferred Stock. The Company shall promptly provide the Holder hereof with any restatement, amendment or modification to the Articles promptly after the same has been made. 

  
 3. 









 11. Mergers and Reclassifications. Subject to the expiration provisions of
Section 7, if after the date hereof the Company shall enter into any Reorganization (as hereinafter defined), then, as a condition of such Reorganization, lawful provisions shall be made, and duly executed documents evidencing the same
from the Company or its successor shall be delivered to the Holder, so that the Holder shall thereafter have the right to purchase, at a total price not to exceed that payable upon the exercise of this Warrant in full, the kind and amount of shares
of stock and other securities and property receivable upon such Reorganization by a holder of the number of shares of Preferred Stock which might have been purchased by the Holder immediately prior to such Reorganization, and in any such case
appropriate provisions shall be made with respect to the rights and interest of the Holder to the end that the provisions hereof (including without limitation, provisions for the adjustment of the Purchase Price and the number of shares issuable
hereunder and the provisions relating to the net issue election) shall thereafter be applicable in relation to any shares of stock or other securities and property thereafter deliverable upon exercise hereof. For the purposes of this
Section 11, the term “Reorganization” shall include without limitation any reclassification, capital reorganization or change of the Preferred Stock (other than a Merger as defined in Section 7 or as a result
of a subdivision, combination or stock dividend provided for in Section 9 hereof). 
 12. Certificate of
Adjustment. Whenever the Purchase Price is adjusted, as herein provided, the Company shall promptly deliver to the Holder a certificate of the Company’s chief financial officer setting forth the Purchase Price after such adjustment and
setting forth a brief statement of the facts requiring such adjustment. 
 13. Notices of Record Date, Etc. In the event
of: 
 (a) any taking by the Company of a record of the holders of any class of securities for the purpose of determining
the holders thereof who are entitled to receive any dividend or other distribution, or any right to subscribe for, purchase, sell or otherwise acquire or dispose of any shares of stock of any class or any other securities or property, or to receive
any other right; 
 (b) any reclassification of the capital stock of the Company, capital reorganization of the Company,
consolidation or merger involving the Company, or sale or conveyance of all or substantially all of its assets; or 
 (c)
any voluntary or involuntary dissolution, liquidation or winding-up of the Company; 
 then in each such event the Company will provide or
cause to be provided to the Holder a written notice thereof. Such notice shall be provided at least twenty (20) business days prior to the date specified in such notice on which any such action is to be taken. 

14. Representations, Warranties and Covenants. This Warrant is issued and delivered by the Company and accepted by each Holder on
the basis of the following representations, warranties and covenants made by the Company: 
 (a) The Company has all
necessary authority to issue, execute and deliver this Warrant and to perform its obligations hereunder. This Warrant has been duly authorized issued, executed and delivered by the Company and is the valid and binding obligation of the Company,
enforceable in accordance with its terms. 
 (b) The shares of Preferred Stock issuable upon the exercise of this Warrant
have been duly authorized and reserved for issuance by the Company and, when issued in accordance with the terms hereof, will be validly issued, fully paid and nonassessable. 
 (c) The issuance, execution and delivery of this Warrant do not, and the issuance of the shares of Preferred Stock upon the exercise of this Warrant in accordance with the terms hereof will not,
(i) violate or contravene the Company’s Articles or by-laws, or any law, statute, regulation, rule, judgment or order applicable to the Company, (ii) violate, contravene or result in a breach or default under any contract, agreement
or instrument to which the Company is a party or by which the Company or any of its assets are bound or (iii) require the consent or approval of or the filing of any notice or registration with any person or entity. 

  
 4. 









 (d) As long as this Warrant is, or any shares of Preferred Stock issued upon exercise
of this Warrant or any shares of Common Stock issued upon conversion of such shares of Preferred Stock are, issued and outstanding, the Company will provide to the Holder (i) as soon as practicable, but in any event within 190 days after the
end of each fiscal year of the Company, an income statement for such fiscal year, a balance sheet of the Company and statement of stockholder’s equity as of the end of such year, and a statement of cash flows for such year, plus, where
applicable, comparisons to the annual budget and operating plan approved by the Board of Directors; such year-end financial reports to be in reasonable detail, prepared in accordance with generally accepted accounting principles in the United States
(“GAAP”), and audited and certified by an independent public accounting firm of nationally or regionally recognized standing selected by the Board of Directors; and (ii) as soon as practicable, but in any event within 30 days after
the end of each of the first three quarters of each fiscal year, an unaudited profit or loss statement, a statement of cash flows for such fiscal quarter and an unaudited balance sheet as of the end of such fiscal quarter, plus, where applicable,
quarterly comparisons to the annual budget and operating plan approved by the Board of Directors; such unaudited financial statements to be prepared in accordance with GAAP consistently applied with prior practice for earlier periods (with the
exception of footnotes that may be required by GAAP) and that fairly present the financial condition of the Company and its results of operation for the period specified, subject to year-end audit adjustment. 

(e) As of the date hereof, the authorized capital stock of the Company consists of (i) 40,200,000 shares of Common Stock, of
which (x) 17, 350,000 shares are issued and outstanding, (y) 323,500 shares have been approved and authorized for sale and issuance by the Company (and which, upon issuance, shall be subject to the terms and conditions of applicable
restricted stock agreements, and (z) and 200,000 shares are reserved for issuance upon the exercise of this Warrant with respect to Common Stock and the conversion of the Preferred Stock into Common Stock if this Warrant is exercised with
respect to Preferred Stock, and (ii) 25,200,000 shares of Series A Preferred Stock, of which 7,000,000 shares are issued and outstanding. Attached hereto as Exhibit B is a capitalization table summarizing the capitalization
of the Company as of November 1, 2010. Once per calendar quarter and upon request from Holder, the Company will provide Holder with a current capitalization table indicating changes, if any, to the number of outstanding shares of common stock
and preferred stock. 
 15. Registration Rights. The Company grants to the Holder all the rights of a “Holder”
under Section 2.2 of the Company’s Investors’ Rights Agreement dated as of March 30, 2010 and shall treat the shares of Common Stock issuable upon conversion of the shares of Preferred Stock issuable upon exercise of this Warrant
as “Registrable Securities,” as described therein. 
 16. Amendment. The terms of this Warrant may be
amended, modified or waived only with the written consent of the Holder and the Company. 
 17. Representations, Warranties
and Covenants of the Holder. This Warrant has been entered into by the Company in reliance upon the following representations and covenants of the Holder, which by its execution hereof the Holder hereby confirms: 

(a) Investment Purpose. The right to acquire Preferred Stock or the Preferred Stock issuable upon exercise of the Holder’s
rights contained herein will be acquired for investment and not with a view to the sale or distribution of any part thereof, and the Holder has no present intention of selling or engaging in any public distribution of the same except pursuant to a
registration or exemption. 
 (b) Accredited Investor. Holder is an “accredited investor” within the meaning of
the Securities and Exchange Rule 501 of Regulation D, as presently in effect. 
 (c) Private Issue. The Holder
understands (i) that the Preferred Stock issuable upon exercise of the Holder’s rights contained herein is not registered under the 1933 Act or qualified under applicable state securities laws on the ground that the issuance contemplated
by this Warrant will be exempt from the registration and qualifications requirements thereof, and (ii) that the Company’s reliance on such exemption is predicated on the representations set forth in this Section 17. 

(d) Financial Risk. The Holder has such knowledge and experience in financial and business matters as to be capable of evaluating
the merits and risks of its investment and has the ability to bear the economic risks of its investment. 

  
 5. 









 (e) Information. The Holder acknowledges that it has been afforded the opportunity to
meet with the management of the Company and to ask question of, and receive answers from, such management about the business and affairs of the Company and concerning the terms and conditions of the offering of this Warrant, and to obtain any
additional information, necessary to verify the accuracy of the information otherwise obtained by or furnished to the Holder in connection with the offering of this Warrant. The Holder agrees that the Company has furnished to the Holder all
information which the Holder considered necessary t form a decision concerning the purchase of this Warrant, and no request to the Company by the Holder for information of any kind about the Company has been refused or denied by the Company or
remains unfulfilled as of the date hereof. 
 (f) Legends. The Holder acknowledges that certificates for securities
purchased under this Warrant shall bear the following legend or a legend substantially similar thereto: 
 THE SHARES OF [SERIES
A PREFERRED STOCK/COMMON STOCK] 
 REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED 

UNDER THE SECURITIES ACT OF 1933, AS AMENDED, AND MAY NOT 
 BE SOLD OR TRANSFERRED UNLESS THE REGISTRATION PROVISIONS 
 OF THE SAID ACT HAVE
BEEN COMPLIED WITH OR UNLESS THE 
 COMPANY HAS RECEIVED AN OPINION OF COUNSEL IN FORM AND 

SUBSTANCE REASONABLY SATISFACTORY TO THE COMPANY TO THE 
 EFFECT THAT COMPLIANCE WITH SUCH PROVISIONS IS NOT REQUIRED. 
 18. Notices,
Transfers, Etc. 
 (a) Any notice or written communication required or permitted to be given to the Holder may be
given by certified mail or delivered to the Holder at the address most recently provided by the Holder to the Company. 
 (b)
Subject to compliance with applicable federal and state securities laws, this Warrant may be transferred by the Holder with respect to any or all of the shares purchasable hereunder. Upon surrender of this Warrant to the Company, together with
the assignment notice annexed hereto duly executed, for transfer of this Warrant as an entirety by the Holder, the Company shall issue a new warrant of the same denomination to the assignee. Upon surrender of this Warrant to the Company, together
with the assignment hereof properly endorsed, by the Holder for transfer with respect to a portion of the shares of Preferred Stock purchasable hereunder, the Company shall issue a new warrant to the assignee, in such denomination as shall be
requested by the Holder hereof, and shall issue to such Holder a new warrant covering the number of shares in respect of which this Warrant shall not have been transferred. 
 (c) In case this Warrant shall be mutilated, lost, stolen or destroyed, the Company shall issue a new warrant of like tenor and denomination and deliver the same (i) in exchange and
substitution for and upon surrender and cancellation of any mutilated Warrant, or (ii) in lieu of any Warrant lost, stolen or destroyed, upon receipt of an affidavit of the Holder or other evidence reasonably satisfactory to the Company of the
loss, theft or destruction of such Warrant 
 19. No Impairment. The Company will not, without the prior written consent
of the Holder, by amendment of its Articles or through any reclassification, capital reorganization, consolidation, merger, sale or conveyance of assets, dissolution, liquidation, issue or sale of securities or any other voluntary action, avoid or
seek to avoid the observance of performance of any of the terms of this Warrant, but will at all times in good faith assist in the carrying out of all such terms and in the taking of all such action as may be necessary or appropriate in order to
protect the rights of the Holder. 
 20. Governing Law. The provisions and terms of this Warrant shall be governed by and
construed in accordance with the internal laws of the State of Delaware without giving effect to its principles regarding conflicts of laws. 
 21. Successors and Assigns. This Warrant shall be binding upon the Company’s successors and assigns and shall inure to the benefit of the Holder’s successors, legal representatives and
permitted assigns. 
 22. Business Days. If the last or appointed day for the taking of any action required or the
expiration of any rights granted herein shall be a Saturday or Sunday or a legal holiday in Massachusetts, then such action may be taken or right may be exercised on the next succeeding day which is not a Saturday or Sunday or such a legal holiday.


  
 6. 









 23. Qualifying Public Offering. If the Company shall effect a firm commitment
underwritten Public Offering of shares of Common Stock which results in the conversion of the Preferred Stock into Common Stock pursuant to the Company’s Articles in effect immediately prior to such offering, then, effective upon such
conversion, this Warrant shall change from the right to purchase shares of Preferred Stock to the right to purchase shares of Common Stock, and the Holder shall thereupon have the right to purchase, at a total price equal to that payable upon the
exercise of this Warrant in full, the number of shares of Common Stock which would have been receivable by the Holder upon the exercise of this Warrant for shares of Preferred Stock immediately prior to such conversion of such shares of Preferred
Stock into shares of Common Stock, and in such event appropriate provisions shall be made with respect to the rights and interest of the Holder to the end that the provisions hereof (including, without limitation, the provisions for the adjustment
of the Purchase Price and of the number of shares purchasable upon exercise of this Warrant and the provisions relating to the net issue election) shall thereafter be applicable to any shares of Common Stock deliverable upon the exercise hereof. In
connection with any such Public Offering, the Holder shall also agree to execute a lock-up agreement if reasonably requested by the Company and the managing underwriter of such offering. 

24. Status of Holder. Except as may be set forth herein or to the extent the Holder may be entitled to certain rights pursuant to
other agreements with the Company or the Company’s stockholders, this Warrant neither entitles the Holder to any rights, voting or otherwise, nor subjects the Holder to any responsibilities or liabilities, as a stockholder of the Company.

 25. Value. The Company and the Holder agree that the value of this Warrant on the date of grant is $100.

  

			
	FOUNDATION MEDICINE, INC.
		
	By:	 	/s/ Alexis Borisy
	Name:	 	Alexis Borisy
	Title:	 	CEO



  
 7. 









 Subscription 
 To:
                                         
            
 Date:
                                         
        
 The undersigned hereby subscribes for
             shares of Preferred Stock covered by this Warrant. The certificate(s) for such shares shall be issued in the name of the undersigned or as otherwise indicated below:

  

	
	  
	Signature
	  
	Name for Registration
	  
	Mailing Address


  
 1. 









 Net Issue Election Notice 

 

			
	To:                             
                                       	  	Date:                          
          

 The undersigned hereby elects under Section 4 to surrender the right to purchase shares of Preferred Stock
pursuant to this Warrant. The certificate(s) for such shares issuable upon such net issue election shall be issued in the name of the undersigned or as otherwise indicated below: 

 

	
	  
	Signature
	  
	Name for Registration
	  
	Mailing Address


  
 1. 









 Assignment 
 For value received
                                         
                                         
                           hereby sells, assigns and transfers unto 

 
  
  

 
 [Please print or typewrite name and address of
Assignee] 
  
  
 the within Warrant, and does hereby irrevocably constitute and appoint
                                        
its attorney to transfer the within Warrant on the books of the within named Company with full power of substitution on the premises. 
 Dated:
                                        

  

	
	  
	Signature
	  
	Name for Registration
	 
	In the Presence of:
	  


  
 1.